Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 11, 2008. The filing addresses Item 5.02 regarding compensatory arrangements for certain executive officers approved by the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Executive Officer | Title | 2008 Annual Base Salary |
|---|---|---|
| Eric Richman | SVP, Business Development and Strategic Planning | $275,126 |
| Christopher C. Camut | VP, Chief Financial Officer | $247,000 |
| Francessa Cook | VP, Policy and Government Affairs | $231,612 |
| Wayne Morges | VP, Regulatory Affairs/Quality Control | $249,757 |
| Valerie Riddle | VP, Medical Director | $268,425 |
| David P. Wright | Chief Executive Officer | $407,680 |
In addition to base salaries, cash bonuses totaling $145,000 were awarded in the aggregate to the five officers listed above (excluding the CEO).
Material Changes
The Board approved a 4% increase to the base salary of CEO David P. Wright, retroactive to January 1, 2008. Base salary levels for other executive officers were also fixed for the 2008 fiscal year.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is limited to the disclosure of executive compensation decisions.
Key Facts for Investor Verification
- Confirm the company name is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc.
- Verify the retroactive effective date of the CEO's salary increase (January 1, 2008).
- Note that the aggregate cash bonus of $145,000 applies to the five non-CEO officers listed.
- Check subsequent filings for any changes to these compensation arrangements or the company's financial status.